Helus Pharma Inc. (HELP) Form 6-K — Nov 5, 2026
Helus Pharma announced that co-founders Eric So and Paul Glavine stepped down from their executive roles on October 26, 2026, with So leaving the President and Executive Chairman positions and Glavine departing as Chief Growth Officer. Both will remain on the board, and So was given the honorary title of Chairman Emeritus. The board appointed Mark Lawson, a director since November 2020 and a private equity and investment banking executive, as independent Chair of the Board effective immediately. The company framed the transition as a natural evolution under recently appointed CEO Michael Halstead.
Key figures
- Phase3 data timing
- Q4 2026 topline data from APPROACH study of HLP003
- Lawson board member since
- November 2020
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.